Incidence and follow-up of persistent lung perfusion abnormalities as a result of suspected air trapping or microthrombosis in non-hospitalised COVID-19 patients during the early half of the pandemic – experience in a tertiary institution in South Afr
DOI:
https://doi.org/10.7196/SAMJ.2022.v112i11.16578Keywords:
COVID-19, respiratory systemAbstract
Background. Available clinical data have revealed that COVID-19 is associated with a risk of pulmonary microthrombosis and small
airway disease, especially in patients with severe disease. These patients present with persistent pulmonary symptoms after recovery, with ventilation and perfusion abnormalities present on several imaging modalities. Few data are available on the occurrence of this complication in patients who earlier presented with a milder form of COVID-19, and their long-term follow-up.
Objective. To assess the incidence of persistent lung perfusion abnormalities as a result of suspected air trapping or microthrombosis in non-hospitalised patients diagnosed with COVID-19. The long-term follow-up of these patients will also be investigated.
Methods. This was a retrospective study conducted at the nuclear medicine department of Universitas Academic Hospital, Bloemfontein. We reviewed the studies of 78 non-hospitalised patients with SARS-CoV-2 infection referred to our department from July 2020 to June 2021 for a perfusion-only single-photon emission computed tomography/computed tomography (SPECT/CT) study or a ventilation perfusion (VQ) SPECT/CT study. All 78 patients were suspected of having pulmonary embolism, and had raised D-dimer levels, with persistent, worsening or new onset of cardiopulmonary symptoms after the diagnosis of COVID-19.
Results. Seventy-eight patients were studied. The median (interquartile range) age was 45 (41 - 58) years and the majority (88.5%) were females. Twenty-two (28.2%) of these patients had matching VQ defects with mosaic attenuation on CT. All 9 of the patients who had follow-up studies had abnormalities that persisted, even after 1 year.
Conclusion. We confirm that persistent ventilation and perfusion abnormalities suspicious of small airway disease and pulmonary
microthrombosis can occur in non-hospitalised patients diagnosed with a milder form of COVID-19. Our study also shows that these
complications remain present even 1 year after the initial diagnosis of COVID-19.
References
Patelli G, Paganoni S, Besana F, et al. Detection of lung hypoperfusion in COVID-19 patients during recovery by digital imaging quantification. medRxiv 2020. https://www.medrxiv.org/content/ early/2020/06/03/2020.05.29.20117143 (accessed 14 May 2022).
Whyte MB, Kelly PA, Gonzalez E, Arya R, Roberts LN. Pulmonary embolism in hospitalised patients with COVID-19. Thromb Res 2020;1(195):95-99. https://doi.org/10.1016%2Fj.thromres.2020.07.025 3. Ortiz ME, Thurman A, Pezzulo AA, et al. Heterogeneous expression of the SARS-Coronavirus-2 receptor
ACE2 in the human respiratory tract. E Bio Med 2020;60:102976. https://doi.org/10.1016/j.ebiom.2020.102976 4. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post- infection by COVID-19: A systematic review and meta-analysis. J Pulmonol 2020;27(4):328-337.
https://doi.org/10.1016/j.pulmoe.2020.10.013
Pednekar P, Amoah K, Homer R, Ryu C, Lutchmansingh DD. Case report: Bullous lung disease following COVID-19. Front Med 2021;8(November):17-20. https://doi.org/10.1016/j.chest.2021.07.358
Guler SA, Ebner L, Aubry-Beigelman C, et al. Pulmonary function and radiological features 4 months after COVID-19: First results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J 2021;57(4):2003690. https://doi.org/10.1183/13993003.03690-2020
EbnerL,Funke-ChambourM,vonGarnierC,FerrettiG,GhayeB,Beigelman-AubryC.Imaginginthe aftermath of COVID-19: What to expect. Eur Radiol 2021;31(6):4390-4392. https://doi.org/10.1007/ s00330-020-07465-6
HuangR,ZhuJ,ZhouJ,etal.Inspiratoryandexpiratorychesthigh-resolutionCT:Small-airwaydisease evaluation in patients with COVID-19. Curr Med Imaging 2021;17:1299-1307. https://doi.org/10.2174/ 1573405617999210112194621
Garg A, Nagpal P, Goyal S, Comellas AP. Small airway disease as long-term sequela of COVID-19: Use of expiratory CT despite improvement in pulmonary function test. medRxiv 2021;2021.10.19.21265028. http://medrxiv.org/content/early/2021/10/22/2021.10.19.21265028.abstract (accessed 12 May 2022).
Burgel PR, Bergeron A, de Blic J, et al. Small airways diseases, excluding asthma and COPD: An overview. Eur Respir Rev 2013;22(128):131-147. https://doi.org/10.1183/09059180.00001313
McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res 2020;127(4):571-587. https://doi.org/10.1161/circresaha.120.317447 12. Patel BV, Arachchillage DJ, Ridge CA, et al. Pulmonary angiopathy in severe COVID-19: Physiologic, imaging, and hematologic observations. Am J Respir Crit Care Med 2020;202(5):690-699. https://doi.
org/10.1164/rccm.202004-1412oc
Sanfilippo F, la Rosa V, Astuto M. Micro-thrombosis, perfusion defects, and worsening oxygenation in COVID-19 patients: A word of caution on the use of convalescent plasma. Mayo Clin Proc 2021;96(1):259. https://doi.org/10.1016/j.mayocp.2020.10.035
Tomashefski JF, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983;112(1):112-126.
Lang ZW, Zhang LJ, Zhang SJ, et al. A clinicopathological study of three cases of severe acute respiratory syndrome (SARS). Pathology 2003;35(6):526-531. https://doi.org/10.1080/00313020310001619118 16. Li K, Wohlford-Lenane C, Perlman S, et al. Middle East respiratory syndrome coronavirus causes
multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect
Dis 2015;212(11):712-722. https://doi.org/10.1093/infdis/jiv499
Evbuomwan O, Engelbrecht G, Bergman MV, Mokwena S, Ayeni OA. Lung perfusion findings on
perfusion SPECT/CT imaging in non-hospitalised de-isolated patients diagnosed with mild COVID-19
infection. Egypt J Radiol Nucl Med 2021;52(1):1-12. https://doi.org/10.1186%2Fs43055-021-00521-1 18. Evbuomwan O, Engelbrecht G, Bergman MV, Mokwena S, Ayeni OA. The prevalence of pulmonary embolism in non-hospitalised de-isolated patients diagnosed with mild COVID-19 disease. S Afr
Med J 2021;111(8):741-746. https://doi.org/10.7196/samj.2021.v111i8.15657
Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, et al. Pathological evidence of pulmonary
thrombotic phenomena in severe COVID-19. J Thromb Haemost 2020;18(6):1517-1519.
Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet
Respir Med 2020; 8(5):518-526. https://doi.org/10.1016/S2213 2600(20)30121-1
Grillet F, Busse-Coté A, Calame P, Behr J, Delabrousse E, Aubry S. COVID-19 pneumonia: Microvascular disease revealed on pulmonary dual-energy computed tomography angiography. Quant Imaging Med Surg 2020;10(9):1852-1862. https://doi.org/10.21037%2Fqims-20-708
Lang M, Som A, Mendoza DP, et al. Hypoxaemia related to COVID-19: Vascular and perfusion abnormalities on dual-energy CT. Lancet Infect Dis 2020;20(12):1365-1366. https://doi.org/10.1016/ S1473-3099(20)30367-4
Santamarina MG, Boisier D, Contreras R, Baque M, Volpacchio M, Beddings I. COVID-19: A hypothesis regarding the ventilation-perfusion mismatch. Crit Care 2020;24(1):395. https://doi. org/10.1186/s13054-020-03125-92020
Borczuk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology: A multi-institutional autopsy cohort from Italy and New York City. Mod Pathol 2020;33(11):2156-2168. https://doi. org/10.1038/s41379-020-00661-1
Downloads
Published
Issue
Section
License
Copyright (c) 2022 O Evbuomwan, W Endres, T Tebieia, G Engelbrecht
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
